NCT00939770 · BASELINE
Baseline characteristics
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 12
- group Id
- BG004
- value
- 38
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 122
- units
- Participants
- groups
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG000
- title
- Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG001
- title
- Phase 1:Part A: PF-02341066 130 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG002
- title
- Phase 1:Part A: PF-02341066 165 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG003
- title
- Phase 1:Part A: PF-02341066 215 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG004
- title
- Phase 1: Part A: PF-02341066 280 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG005
- title
- Phase 1: Part A: PF-02341066 365 mg/m²/Dose BID
- description
- Part B: Patients with ALK+ relapsed/refractory neuroblastoma
- id
- BG006
- title
- Phase 2: Part B: PF-02341066 280 mg/m²/Dose BID
- description
- Part C: Patients with ALK+ relapsed/refractory ALCL
- id
- BG007
- title
- Phase 2: Part C: PF-02341066 280 mg/m²/Dose BID
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 34
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 113
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 9
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 5
- upper Limit
- 12
- value
- 8.5
- group Id
- BG001
- lower Limit
- 6
- upper Limit
- 20
- value
- 12
- group Id
- BG002
- lower Limit
- 1
- upper Limit
- 21
- value
- 8
- group Id
- BG003
- lower Limit
- 3
- upper Limit
- 20
- value
- 11.5
- group Id
- BG004
- lower Limit
- 1
- upper Limit
- 21
- value
- 9
- group Id
- BG005
- lower Limit
- 2
- upper Limit
- 20
- value
- 10
- group Id
- BG006
- lower Limit
- 3
- upper Limit
- 14
- value
- 5.5
- group Id
- BG007
- lower Limit
- 6
- upper Limit
- 15
- value
- 9.5
- group Id
- BG008
- lower Limit
- 1
- upper Limit
- 21
- value
- 9
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 60
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 62
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 13
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 28
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 13
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 98
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 11
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 6
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 12
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 87
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 18
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Complete source fields
- denoms
- counts
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 23
- group Id
- BG003
- value
- 12
- group Id
- BG004
- value
- 38
- group Id
- BG005
- value
- 11
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 122
- units
- Participants
- groups
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG000
- title
- Phase 1: Part A: PF-02341066 100 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG001
- title
- Phase 1:Part A: PF-02341066 130 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG002
- title
- Phase 1:Part A: PF-02341066 165 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG003
- title
- Phase 1:Part A: PF-02341066 215 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG004
- title
- Phase 1: Part A: PF-02341066 280 mg/m²/Dose BID
- description
- Part A1: Patients with relapsed/refractory solid tumors or anaplastic large cell lymphoma (ALCL) Part A2: Patients with recurrent/refractory malignancies who have confirmed ALK fusion proteins, ALK mutations, ALK amplification or evidence for MET mutation or amplification. Once Parts B and C are open to accrual, patients who are not eligible for either Part should enroll on Part A2, Part A3: Patients with recurrent/refractory neuroblastoma, who are not eligible for Part A1 or A2 or who cannot enroll on Part A1 because of stratum suspension or lack of available slots.
- id
- BG005
- title
- Phase 1: Part A: PF-02341066 365 mg/m²/Dose BID
- description
- Part B: Patients with ALK+ relapsed/refractory neuroblastoma
- id
- BG006
- title
- Phase 2: Part B: PF-02341066 280 mg/m²/Dose BID
- description
- Part C: Patients with ALK+ relapsed/refractory ALCL
- id
- BG007
- title
- Phase 2: Part C: PF-02341066 280 mg/m²/Dose BID
- description
- Total of all reporting groups
- id
- BG008
- title
- Total
- measures
- classes
- categories
- measurements
- group Id
- BG000
- value
- 6
- group Id
- BG001
- value
- 7
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 11
- group Id
- BG004
- value
- 34
- group Id
- BG005
- value
- 10
- group Id
- BG006
- value
- 14
- group Id
- BG007
- value
- 10
- group Id
- BG008
- value
- 113
- title
- <=18 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 2
- group Id
- BG003
- value
- 1
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 9
- title
- Between 18 and 65 years
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- >=65 years
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Age, Categorical
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- lower Limit
- 5
- upper Limit
- 12
- value
- 8.5
- group Id
- BG001
- lower Limit
- 6
- upper Limit
- 20
- value
- 12
- group Id
- BG002
- lower Limit
- 1
- upper Limit
- 21
- value
- 8
- group Id
- BG003
- lower Limit
- 3
- upper Limit
- 20
- value
- 11.5
- group Id
- BG004
- lower Limit
- 1
- upper Limit
- 21
- value
- 9
- group Id
- BG005
- lower Limit
- 2
- upper Limit
- 20
- value
- 10
- group Id
- BG006
- lower Limit
- 3
- upper Limit
- 14
- value
- 5.5
- group Id
- BG007
- lower Limit
- 6
- upper Limit
- 15
- value
- 9.5
- group Id
- BG008
- lower Limit
- 1
- upper Limit
- 21
- value
- 9
- dispersion Type
- FULL_RANGE
- param Type
- MEDIAN
- title
- Age, Continuous
- unit Of Measure
- years
- classes
- categories
- measurements
- group Id
- BG000
- value
- 2
- group Id
- BG001
- value
- 3
- group Id
- BG002
- value
- 9
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 5
- group Id
- BG006
- value
- 8
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 60
- title
- Female
- measurements
- group Id
- BG000
- value
- 4
- group Id
- BG001
- value
- 5
- group Id
- BG002
- value
- 14
- group Id
- BG003
- value
- 6
- group Id
- BG004
- value
- 13
- group Id
- BG005
- value
- 6
- group Id
- BG006
- value
- 6
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 62
- title
- Male
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Sex: Female, Male
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 2
- group Id
- BG004
- value
- 6
- group Id
- BG005
- value
- 2
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 13
- title
- Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 8
- group Id
- BG002
- value
- 21
- group Id
- BG003
- value
- 7
- group Id
- BG004
- value
- 28
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 13
- group Id
- BG007
- value
- 8
- group Id
- BG008
- value
- 98
- title
- Not Hispanic or Latino
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 3
- group Id
- BG004
- value
- 4
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 11
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Ethnicity (NIH/OMB)
- unit Of Measure
- Participants
- classes
- categories
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- American Indian or Alaska Native
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 1
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 1
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 1
- group Id
- BG008
- value
- 6
- title
- Asian
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- Native Hawaiian or Other Pacific Islander
- measurements
- group Id
- BG000
- value
- 1
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 5
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 1
- group Id
- BG007
- value
- 3
- group Id
- BG008
- value
- 11
- title
- Black or African American
- measurements
- group Id
- BG000
- value
- 5
- group Id
- BG001
- value
- 6
- group Id
- BG002
- value
- 19
- group Id
- BG003
- value
- 8
- group Id
- BG004
- value
- 25
- group Id
- BG005
- value
- 8
- group Id
- BG006
- value
- 12
- group Id
- BG007
- value
- 4
- group Id
- BG008
- value
- 87
- title
- White
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 0
- group Id
- BG002
- value
- 0
- group Id
- BG003
- value
- 0
- group Id
- BG004
- value
- 0
- group Id
- BG005
- value
- 0
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 0
- group Id
- BG008
- value
- 0
- title
- More than one race
- measurements
- group Id
- BG000
- value
- 0
- group Id
- BG001
- value
- 1
- group Id
- BG002
- value
- 3
- group Id
- BG003
- value
- 4
- group Id
- BG004
- value
- 7
- group Id
- BG005
- value
- 1
- group Id
- BG006
- value
- 0
- group Id
- BG007
- value
- 2
- group Id
- BG008
- value
- 18
- title
- Unknown or Not Reported
- param Type
- COUNT_OF_PARTICIPANTS
- title
- Race (NIH/OMB)
- unit Of Measure
- Participants
Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0
Preserved source evidence · Not medical advice
Triangle